Guardant Health, Inc. (GH)
| Previous Close | 18.82 |
| Open | 18.68 |
| Bid | 18.55 x 100 |
| Ask | 18.64 x 100 |
| Day's Range | 18.47 - 19.10 |
| 52 Week Range | 15.81 - 41.06 |
| Volume | |
| Avg. Volume | 1,944,855 |
| Market Cap | 2.266B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif., May 07, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
- Business Wire
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
PALO ALTO, Calif., May 07, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the industry.
- Business Wire
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
PALO ALTO, Calif., April 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.
